Disturbed Sleep in Pediatric Patients With Leukemia: The Potential Role of Interleukin-6 (−174GC) and Tumor Necrosis Factor (−308GA) Polymorphism

Pamela S. Hinds, PhD, RN, FAAN, and Belinda N. Mandrell, PhD, RN

Pediatric patients with cancer have rated disrupted sleep and fatigue as two of the most distressing symptoms related to their illness and treatment (Hinds et al., 1999; Hinds, Hockenberry, Gattuso, et al., 2007). These disturbances can persist for years after treatment for acute lymphoblastic leukemia (ALL), with as many as 50% of ALL survivors reporting sleep problems more than 10 years after completion of anticancer therapy (Meeske, Siegel, Globe, Mack, & Bernstein, 2005). Sleep disturbances in patients with cancer are common but often are undiagnosed or assumed to be a tolerable side effect of cancer or its treatment (Rosen, Shor, & Geller, 2008). Several studies have demonstrated poor sleep efficiency in pediatric patients undergoing cancer treatment, with an average sleep efficiency of 84% in patients with ALL who were in their home environment and 72% in patients with acute myelogenous leukemia or solid tumors who were in a hospital environment (Hinds, Hockenberry, Gattuso, et al., 2007; Hinds, Hockenberry, Rai, Zhang, Raazzouk, Cremer, et al., 2007; Hinds, Hockenberry, Rai, Zhang, Raazzouk, McCarthy, et al., 2007). Hinds, Hockenberry, Gattuso, et al. (2007) documented poor sleep quality and high levels of fatigue in children and adolescents at home during continuation chemotherapy for ALL. The study found that these patients stayed in bed longer, had poorer sleep efficiency, and had more nocturnal awakenings than cohorts of healthy children and adolescents. Given the detrimental effects of poor sleep on the immune system and cognitive development, the authors of this current article believe that decreased sleep quality is a crucial area to explore in pediatric patients with cancer. Therefore, the authors proposed a biobehavioral model of disrupted sleep in that genetic variability of selected inflammatory mediators might predict at-risk pediatric patients with cancer. The study framework was the Human Response Model, which integrates biopsychological factors, individual characteristics that may or may not...